Verrica Pharmaceuticals (VRCA) Projected to Announce Quarterly Earnings on Thursday

Verrica Pharmaceuticals (NASDAQ:VRCA) is expected to be releasing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.41) per share and revenue of $5.7330 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Verrica Pharmaceuticals (NASDAQ:VRCA) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.18. Verrica Pharmaceuticals had a negative net margin of 47.97% and a negative return on equity of 1,077.78%. The business had revenue of $5.02 million during the quarter, compared to analyst estimates of $4.51 million. On average, analysts expect Verrica Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Verrica Pharmaceuticals Trading Up 3.4%

NASDAQ VRCA traded up $0.18 on Tuesday, hitting $5.43. The company’s stock had a trading volume of 4,142 shares, compared to its average volume of 93,883. The company has a quick ratio of 1.98, a current ratio of 2.10 and a debt-to-equity ratio of 0.03. Verrica Pharmaceuticals has a 1-year low of $3.28 and a 1-year high of $9.82. The firm has a market cap of $93.30 million, a PE ratio of -5.28 and a beta of 1.49. The company’s 50-day moving average is $5.84 and its 200 day moving average is $6.10.

Analyst Upgrades and Downgrades

VRCA has been the subject of a number of recent analyst reports. HC Wainwright assumed coverage on shares of Verrica Pharmaceuticals in a research report on Tuesday, May 26th. They set a “buy” rating and a $12.00 target price for the company. Zacks Research raised shares of Verrica Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, May 11th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, July 15th. Finally, Wall Street Zen downgraded shares of Verrica Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, July 25th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $14.50.

Institutional Trading of Verrica Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Man Group plc acquired a new position in shares of Verrica Pharmaceuticals during the 4th quarter valued at $94,000. Quadrature Capital Ltd bought a new stake in Verrica Pharmaceuticals in the fourth quarter valued at $99,000. Beck Mack & Oliver LLC acquired a new position in shares of Verrica Pharmaceuticals during the fourth quarter valued at about $100,000. Bridgeway Capital Management LLC acquired a new position in shares of Verrica Pharmaceuticals during the third quarter valued at about $52,000. Finally, XTX Topco Ltd bought a new position in shares of Verrica Pharmaceuticals during the 4th quarter worth about $122,000. Institutional investors own 42.45% of the company’s stock.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.